You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

20 Results
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-32
Jan 2021
Drug
Other Name(s): Matulane®
Dec 2019
Drug
Other Name(s): Ibrance™
May 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant, Curative, Palliative
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Jun 2021
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
May 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Sep 2019
Drug
Other Name(s): Mozobil®
Jun 2019
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Jun 2021

Pages